SpyGlass Pharma

Historical price data

SpyGlass Pharma is developing a transformative solution for the concurrent treatment of glaucoma and cataracts, two leading causes of vision loss. Its proprietary BIM-IOL System combines a standard monofocal intraocular lens with non-bioerodible drug-eluting pads that release bimatoprost directly into the eye for up to three years. This approach aims to eliminate the need for daily eye drops, overcoming the major challenge of patient non-adherence. By integrating therapy into a common surgical procedure, SpyGlass seeks to enable all cataract surgeons to treat glaucoma, potentially expanding access to effective, long-term intraocular pressure control.

A proprietary sustained drug delivery platform integrating non-bioerodible drug-eluting pads with an intraocular lens (IOL), designed to release medication directly into the eye over multiple years following implantation during cataract surgery.

3 drugs in pipeline, 2 in Phase 3

Total raised: $205M

Main competitors include topical prostaglandin analogs (standard of care), MIGS devices (e.g., iStent, Hydrus), and other sustained-release implants (e.g., Durysta, OTX-TIC). SpyGlass differentiates through its multi-year (3-year) drug delivery integrated directly into the cataract IOL, requiring no specialized surgical technique beyond standard cataract surgery.